Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | FDFT1 | P37268 | 4/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 4/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546674 | 0.93 | HDAC2 (0.56) | FFAR1FDFT1HDAC2HDAC1MMP12 | |
| SCHEMBL5534572 | 0.91 | HDAC2 (0.57) | FFAR1FDFT1HDAC2HDAC1MMP12 | |
| SCHEMBL5540190 | 0.91 | HDAC2 (0.57) | FFAR1FDFT1HDAC2HDAC1MMP12 | |
| SCHEMBL5539870 | 0.86 | FFAR1 (0.59) | FFAR1FDFT1HDAC2MMP12ABCC4 | |
| SCHEMBL1544 | 0.85 | ALDH1A1 (0.57) | HDAC2HDAC1 | |
| SCHEMBL30869989 | 0.85 | HDAC2 (0.60) | FFAR1FDFT1HDAC2HDAC1ABCC4 | |
| SCHEMBL9826765 | 0.83 | HTR2A (0.62) | FFAR1FDFT1HDAC2HDAC1MMP12 | |
| SCHEMBL24372592 | 0.82 | FFAR1 (0.50) | FFAR1FDFT1HDAC2HDAC1MMP12 | |
| SCHEMBL8619956 | 0.82 | ALDH1A1 (0.54) | FFAR1FDFT1HDAC2HDAC1MMP12 | |
| SCHEMBL8622458 | 0.82 | ALDH1A1 (0.54) | FFAR1FDFT1HDAC2HDAC1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597784-B2 | Enhanced yield, structural control, and transport properties of polynorbornenes for natural gas upgrading through Mizoroki-Heck cross-couplings | SAUDI ARABIAN OIL COMPANY (SA) | 2023-03-07 | — | — | US | disclosed |
| US-20210324118-A1 | ENHANCED YIELD, STRUCTURAL CONTROL, AND TRANSPORT PROPERTIES OF POLYNORBORNENES FOR NATURAL GAS UPGRADING THROUGH MIZOROKI-HECK CROSS-COUPLINGS | SAUDI ARABIAN OIL COMPANY (SA) | 2021-10-21 | — | — | US | disclosed |
| WO-2021202343-A1 | ENHANCED YIELD, STRUCTURAL CONTROL, AND TRANSPORT PROPERTIES OF POLYNORBORNENES FOR NATURAL GAS UPGRADING THROUGH MIZOROKI-HECK CROSS-COUPLINGS | SAUDI ARABIAN OIL COMPANY (SA) | 2021-10-07 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597784-B2 | Enhanced yield, structural control, and transport properties of polynorbornenes for natural gas upgrading through Mizoroki-Heck cross-couplings | PNKP, GRK1, LNPK | FFAR1 1522/4885FDFT1 1544/4885HDAC2 4585/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | FFAR1 105/4885FDFT1 852/4885HDAC2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.